Saturday, December 3, 2022


Biotechnology News Magazine


ImprimisRx Launches Fortisite ™ (Tobramycin 1.5% + Vancomycin 5%) Compounded Antibiotic Formulation

Fortisite includes a patent-pending compounded combination of Tobramycin 1.5% and Vancomycin 5%.

CNBX Pharmaceuticals Announces New Patent Granted in Australia

CNBX Pharmaceuticals said the notice relates to the Company's patent titled: System and Method for High Throughput Screening of Cancer Cells. The term of the patent granted is set for 20 years starting May 2016 and until May 2036.

XNK Therapeutics to Use Generic Name Evencaleucel for Lead Candidate

Evencaleucel was recently recommended by the World Health Organization (WHO) as the International Nonproprietary Name (INN) for XNK's leading drug candidate.

Neuren Pharmaceuticals Reports: Rett Syndrome New Drug Application Granted FDA Priority Review

If the NDA is approved by the FDA, Neuren expects to earn revenue over 2022 and 2023 for Rett syndrome in the US alone of A$118 million plus double-digit percentage royalties on net sales reports Neuren Pharmaceuticals.

PhoreMost Enters Multi-project Drug Target Discovery Collaboration with Roc

Under the terms of the agreement, PhoreMost will receive an upfront payment and is eligible for preclinical success-based milestones. Further financial terms are not disclosed.

Junshi Biosciences Announces FDA Approval of Investigational New Drug Application for JS110 (XPO1 inhibitor)

This is the 7th innovative drug in Junshi Biosciences’ pipeline to get IND approval from the US FDA